Bone Biologics Corporation (BBLG) Operating income 2016–2025
Bone Biologics Corporation (BBLG) annual operating income history from SEC filings — each fiscal year as reported.
-$3.2MFY2025 · since FY2016: -$20.4M → -$3.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.2M | +23.3% |
| FY2024 | -$4.2M | +55.3% |
| FY2023 | -$9.4M | -157.2% |
| FY2022 | -$3.7M | -232.3% |
| FY2021 | -$1.1M | -33.7% |
| FY2020 | -$825,014 | +66.3% |
| FY2019 | -$2.4M | +12.3% |
| FY2018 | -$2.8M | -6.3% |
| FY2017 | -$2.6M | +87.1% |
| FY2016 | -$20.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BBLG financial trends
BBLG RevenueBBLG Net incomeBBLG Net marginBBLG Gross profitBBLG Gross marginBBLG Operating marginBBLG Operating cash flowBBLG Free cash flowBBLG Capital expendituresBBLG Return on equityBBLG Stock buybacksBBLG Dividends paidBBLG Total assetsBBLG Total liabilitiesBBLG Shareholders’ equityBBLG overview →